NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ViaNautis Bio

ViaNautis Bio

Private
CambridgeHealthcare & Life Scienceshttps://vianautis.com/

Last Round

Series A

Nov 13, 2023

Total Funding Raised

$27.89M

Company Overview

ViaNautis Bio is a biotechnology company developing a nanomedicine platform to deliver genetic therapies across biological barriers for diseases such as cystic fibrosis and central nervous system disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Advanced Materials

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

drug delivery platformnon-viral deliverynon-viral vectorgene deliverynanomedicinemRNA deliveryblood-brain barrier deliverypolymer nanoparticlestargeted drug deliverydrug delivery vehiclepre-clinical biotechcentral nervous system therapiesCNS therapiescystic fibrosis therapyLNP alternativesiRNA deliveryDNA deliveryin vivo CAR-T

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ViaNautis Bio Comparables

Compare ViaNautis Bio with similar companies based on industry and business-model similarity.

ViaNautis Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Genedit
88%
Nanite, Inc.
84%
Deliver Biosciences
80%

ViaNautis Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 13, 2023
SeedMar 29, 2021

Key People

Founding team and executive leadership

Adi Hoess

Chief Executive Officer

Executive Team

Denis Cecchin

Chief Technology Officer

Executive Team

ViaNautis Bio Investors

Notable investors and investment history

ViaNautis Bio investors
InvestorRounds
UCB VenturesSeries A
BGFSeries A
Origin CapitalSeries A, Seed
o2h venturesSeries A, Seed
4BIO CapitalSeries A
Meltwind AdvisorySeries A, Seed
Cystic Fibrosis FoundationSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 13, 2025

    Grew 18% QoQ, from 38 to 45 employees.

  • Jan 15, 2025

    Grew 25% QoQ, from 32 to 40 employees.

ViaNautis Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ViaNautis Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ViaNautis Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range46
Year Founded2018
Last FundingNov 13, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.